198 related articles for article (PubMed ID: 32056107)
1. Hemolysis and Fetal Fraction in Cell-Free DNA Blood Collection Tubes for Noninvasive Prenatal Testing.
Stokowski R; White K; Hacker C; Doshi J; Schmid M
Mol Diagn Ther; 2020 Apr; 24(2):185-190. PubMed ID: 32056107
[TBL] [Abstract][Full Text] [Related]
2. Sequencing shorter cfDNA fragments improves the fetal DNA fraction in noninvasive prenatal testing.
Qiao L; Yu B; Liang Y; Zhang C; Wu X; Xue Y; Shen C; He Q; Lu J; Xiang J; Li H; Zheng Q; Wang T
Am J Obstet Gynecol; 2019 Oct; 221(4):345.e1-345.e11. PubMed ID: 31125545
[TBL] [Abstract][Full Text] [Related]
3. Improving Fetal Fraction of Noninvasive Prenatal Screening Samples Collected in EDTA-Gel Tubes Using Gel Size Selection: A Head-To-Head Comparison of Methods.
Daryabari SS; Giroux S; Caron A; Chau B; Langlois S; Rousseau F
J Mol Diagn; 2022 Sep; 24(9):955-962. PubMed ID: 35820622
[TBL] [Abstract][Full Text] [Related]
4. Obesity and no call results: optimal timing of cell-free DNA testing and redraw.
Hopkins MK; Koelper N; Caldwell S; Dyr B; Dugoff L
Am J Obstet Gynecol; 2021 Oct; 225(4):417.e1-417.e10. PubMed ID: 33839096
[TBL] [Abstract][Full Text] [Related]
5. Performance of ImproGene Cell-Free DNA Tubes for Stabilization and Analysis of cfDNA in Blood Samples.
Luo J; Wang S; Zhang S; He Y; Li S; Han J; Xu M; Deng G
Fetal Pediatr Pathol; 2022 Oct; 41(5):771-780. PubMed ID: 34547970
[TBL] [Abstract][Full Text] [Related]
6. The Effect of In Vitro Hemolysis on Measurement of Cell-Free DNA.
Nishimura F; Uno N; Chiang PC; Kaku N; Morinaga Y; Hasegawa H; Yanagihara K
J Appl Lab Med; 2019 Sep; 4(2):235-240. PubMed ID: 31639669
[TBL] [Abstract][Full Text] [Related]
7. The effect of hemolysis on quality control metrics for noninvasive prenatal testing.
Guo Y; Yu D; Zhou K; Wang J; Lei D; Xu Z; Tang W; Wu M; Fang X; Shen J; Peng Z; Xiang J
BMC Med Genomics; 2022 Jun; 15(1):125. PubMed ID: 35659298
[TBL] [Abstract][Full Text] [Related]
8. Most noninvasive prenatal screens failing due to inadequate fetal cell free DNA are negative for trisomy when repeated.
Lopes JL; Lopes GS; Enninga EAL; Kearney HM; Hoppman NL; Rowsey RA
Prenat Diagn; 2020 Jun; 40(7):831-837. PubMed ID: 32274800
[TBL] [Abstract][Full Text] [Related]
9. Performance of a targeted cell-free DNA prenatal test for 22q11.2 deletion in a large clinical cohort.
Bevilacqua E; Jani JC; Chaoui R; Suk EA; Palma-Dias R; Ko TM; Warsof S; Stokowski R; Jones KJ; Grati FR; Schmid M
Ultrasound Obstet Gynecol; 2021 Oct; 58(4):597-602. PubMed ID: 34090308
[TBL] [Abstract][Full Text] [Related]
10. Association between cell-free DNA fetal fraction and gestational diabetes.
Hopkins MK; Koelper N; Bender W; Durnwald C; Sammel M; Dugoff L
Prenat Diagn; 2020 May; 40(6):724-727. PubMed ID: 32091624
[TBL] [Abstract][Full Text] [Related]
11. Validation of a New Protocol to Collect and Isolate Plasma from Pregnant Women for Noninvasive Prenatal Testing (NIPT).
Giroux S; Badeau M; Jeuken J; Caron A; Girouard J; Rousseau F
J Appl Lab Med; 2021 Apr; 6(3):743-749. PubMed ID: 33215208
[TBL] [Abstract][Full Text] [Related]
12. The impact of maternal autoimmune disease on cell-free DNA test characteristics.
MacKinnon HJ; Kolarova TR; Katz R; Hedge JM; Vinopal E; Lockwood CM; Shree R; Delaney S
Am J Obstet Gynecol MFM; 2021 Nov; 3(6):100466. PubMed ID: 34418590
[TBL] [Abstract][Full Text] [Related]
13. Performance comparison of blood collection tubes as liquid biopsy storage system for minimizing cfDNA contamination from genomic DNA.
Zhao Y; Li Y; Chen P; Li S; Luo J; Xia H
J Clin Lab Anal; 2019 Feb; 33(2):e22670. PubMed ID: 30191594
[TBL] [Abstract][Full Text] [Related]
14. The influence of fetal gender and maternal characteristics on fetal cell-free DNA in maternal plasma.
Zhao Q; HuoJiaBieKe J; Du S
J Gynecol Obstet Hum Reprod; 2019 Oct; 48(8):653-656. PubMed ID: 31276844
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting cell-free DNA fetal fraction: statistical analysis of 13,661 maternal plasmas for non-invasive prenatal screening.
Hou Y; Yang J; Qi Y; Guo F; Peng H; Wang D; Wang Y; Luo X; Li Y; Yin A
Hum Genomics; 2019 Dec; 13(1):62. PubMed ID: 31801621
[TBL] [Abstract][Full Text] [Related]
16. A novel approach to stabilize fetal cell-free DNA fraction in maternal blood samples for extended period of time.
Fernando MR; Jiang C; Krzyzanowski GD; Somer-Shely T; Ryan WL
PLoS One; 2018; 13(12):e0208508. PubMed ID: 30521613
[TBL] [Abstract][Full Text] [Related]
17. A proof-of-concept study on the effects of low total cfDNA content and solutions to increase the NIPT trisomy 21 detection rate.
Du Y; Chen A; Yang R; Zhou T; Zhou Q; Yang L; Wang J; Hong Y; Chen C; Wan Q; Yang L; Chen Y
J Clin Lab Anal; 2020 Feb; 34(2):e23035. PubMed ID: 31568605
[TBL] [Abstract][Full Text] [Related]
18. The fragmentation patterns of maternal plasma cell-free DNA and its applications in non-invasive prenatal testing.
Pan M; Chen P; Lu J; Liu Z; Jia E; Ge Q
Prenat Diagn; 2020 Jul; 40(8):911-917. PubMed ID: 32147843
[TBL] [Abstract][Full Text] [Related]
19. Cell-free fetal DNA analysis in maternal plasma as screening test for trisomies 21, 18 and 13 in twin pregnancy.
Le Conte G; Letourneau A; Jani J; Kleinfinger P; Lohmann L; Costa JM; Benachi A
Ultrasound Obstet Gynecol; 2018 Sep; 52(3):318-324. PubMed ID: 28833712
[TBL] [Abstract][Full Text] [Related]
20. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
Miltoft CB; Rode L; Ekelund CK; Sundberg K; Kjaergaard S; Zingenberg H; Tabor A
Ultrasound Obstet Gynecol; 2018 Apr; 51(4):470-479. PubMed ID: 28640470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
